Wellell Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Daniel Lee

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	0.8%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.3yrs

Jüngste Management Updates

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Mar 29

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Mar 01

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Feb 11

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Jan 27

Is Apex Medical (TPE:4106) Using Too Much Debt?

Jan 12

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Dec 28

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Nov 27

Geschäftsführer

Daniel Lee

no data

Amtszeit

Mr. Daniel Lee is Founder and CEO of Wellell Inc. He was President, GM & Chairman of Wellell Inc. from August 01, 2021. He was President & Chairman of Wellell Inc. until August 01, 2021. Mr. Lee was Sales...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yong-Chuan Li	Chairman of the Board & GM	no data	keine Daten	1.4% NT$ 37.4m
James Wang	Independent Director	5.3yrs	keine Daten	keine Daten
Wan Lin	Independent Director	11.3yrs	keine Daten	keine Daten
Yan Zhou	Supervisors	no data	keine Daten	keine Daten
Jin Li	Supervisor	no data	keine Daten	keine Daten
Der-Zen Liu	Representative Director	no data	keine Daten	keine Daten
Hsiung-Ching Lee	Independent Director	5.3yrs	keine Daten	keine Daten
Charles Liu	Director	no data	keine Daten	keine Daten
William Wang	Independent Director	no data	keine Daten	keine Daten
Peter Lin	Independent Director	no data	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: 4106Die Vorstandsmitglieder gelten als erfahren (4.9 Jahre durchschnittliche Amtszeit).

Wellell Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Wellell Inc. Appoints Su Ya-Ling as Chief Operating Officer

Wellell Inc., Annual General Meeting, Jun 24, 2024

Wellell Inc. Appoints Lee Pi Kai as Chief Strategy Officer

Wellell Inc. Announces Resignation of Tan, Jian-Qiang as Chief Operating Officer

Wellell Inc. Appoints Shin-Ho,Chen as Corporate Governance Officer

Insufficient new directors

Recent updates

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: NT$0.21 (vs NT$0.50 in 2Q 2023)

Wellell Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$0.80 per share

Wellell's (TWSE:4106) Dividend Is Being Reduced To NT$0.80

Wellell (TWSE:4106) Has Announced That Its Dividend Will Be Reduced To NT$0.80

Dividend reduced to NT$0.80

Wellell Inc. Approves Common Stock Cash Dividend, Payable on August 26, 2024

First quarter 2024 earnings released: EPS: NT$0.40 (vs NT$0.50 in 1Q 2023)

Wellell Inc. to Report Q1, 2024 Results on May 08, 2024

Wellell Inc. to Report Q1, 2024 Results on May 08, 2024

Some May Be Optimistic About Wellell's (TWSE:4106) Earnings

Wellell Inc. Appoints Su Ya-Ling as Chief Operating Officer

Full year 2023 earnings released: EPS: NT$1.51 (vs NT$1.60 in FY 2022)

Wellell Inc., Annual General Meeting, Jun 24, 2024

Wellell Inc. Appoints Lee Pi Kai as Chief Strategy Officer

Wellell Inc. Announces Resignation of Tan, Jian-Qiang as Chief Operating Officer

Second quarter 2023 earnings released: EPS: NT$0.50 (vs NT$0.51 in 2Q 2022)

Upcoming dividend of NT$0.85 per share at 2.7% yield

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 16%

Wellell Inc. Appoints Shin-Ho,Chen as Corporate Governance Officer

Full year 2022 earnings released: EPS: NT$1.60 (vs NT$1.01 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.59 (vs NT$0.31 in 3Q 2021)

Insufficient new directors

Wellell Inc. Announces Change Member of Remuneration Committee

Second quarter 2022 earnings released: EPS: NT$0.51 (vs NT$0.34 in 2Q 2021)

Insufficient new directors

Apex Medical Corp. Approves Cash Dividend for the Year 2021

Apex Medical Corp. Announces Change of Alan Chang as Research and Development Officer, Effective May 31, 2022

Apex (Kunshan)Medical Corp. to Announce Production Can Be Resume Gradually

Apex Medical Corp. Announces On Behalf of the Subsidiaries Apex (Kunshan) Medical Corp. and Wellell (Kunshan) Co., Ltd. Extend Temporary Suspension of Production

Wellell (Kunshan) Co., Ltd. Announces the Temporary Suspension of Production

Full year 2021 earnings released: EPS: NT$1.01 (vs NT$1.04 in FY 2020)

Wellell Inc., Annual General Meeting, Jun 20, 2022

Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.28 in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

Upcoming dividend of NT$0.55 per share

Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.55 in 2Q 2020)

High number of new directors

High number of new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.29 (vs NT$0.074 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.04 (vs NT$0.87 in FY 2019)

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Apex Medical Corp. Announces Executive Changes, Effective March 01, 2021

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Apex Medical Corp. Appoints Alan Chang as Director of R&D

New 90-day low: NT$25.65

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Is Apex Medical (TPE:4106) Using Too Much Debt?

New 90-day low: NT$28.00

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

New 90-day low: NT$28.90

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$31.05

First half earnings released

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit